Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Authors
Keywords
-
Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 371, Issue 11, Pages 1005-1015
Publisher
New England Journal of Medicine (NEJM/MMS)
Online
2015-01-26
DOI
10.1056/nejmoa1403088
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL
- (2013) A. van der Veer et al. BLOOD
- Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion
- (2013) E. Lengline et al. HAEMATOLOGICA
- Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB–Positive Acute Lymphoblastic Leukemia
- (2013) Brent W. Weston et al. JOURNAL OF CLINICAL ONCOLOGY
- Acute lymphoblastic leukaemia
- (2013) Hiroto Inaba et al. LANCET
- Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells
- (2013) Mikko Taipale et al. NATURE BIOTECHNOLOGY
- A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia
- (2013) Sohela Shah et al. NATURE GENETICS
- Genomic Characterization of Childhood Acute Lymphoblastic Leukemia
- (2013) Charles G. Mullighan SEMINARS IN HEMATOLOGY
- Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia
- (2012) S. K. Tasian et al. BLOOD
- Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project
- (2012) M. L. Loh et al. BLOOD
- Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
- (2012) S. L. Maude et al. BLOOD
- Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
- (2012) Kathryn G. Roberts et al. CANCER CELL
- Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia
- (2011) Thomas Ernst et al. BRITISH JOURNAL OF HAEMATOLOGY
- Adolescents and Young Adults with Acute Lymphoblastic Leukemia
- (2011) W. Stock Hematology-American Society of Hematology Education Program
- Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia
- (2010) R. C. Harvey et al. BLOOD
- Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia
- (2009) L. J. Russell et al. BLOOD
- Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
- (2009) Kirk R. Schultz et al. JOURNAL OF CLINICAL ONCOLOGY
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
- (2009) Monique L Den Boer et al. LANCET ONCOLOGY
- Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia
- (2009) Charles G Mullighan et al. NATURE GENETICS
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia
- (2009) Charles G. Mullighan et al. NEW ENGLAND JOURNAL OF MEDICINE
- NovelSSBP2-JAK2fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia
- (2008) Jennifer L. Poitras et al. GENES CHROMOSOMES & CANCER
- BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
- (2008) Charles G. Mullighan et al. NATURE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started